Patients with schizophrenia-spectrum disorders have differing inflammatory marker levels compared with healthy controls. These results from a systematic review and meta-analysis were published in The Lancet Psychiatry.
Patients with schizophrenia-spectrum disorders have differing inflammatory marker levels compared with healthy controls. These results from a systematic review and meta-analysis were published in The Lancet Psychiatry.